---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092265"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:39:39.439313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program

## Summary
- Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
- Cash, equivalents and marketable securities $226.1M at June 30; projected runway into 2026.
- Open-label extension study all 7 sites activated; interim data planned Q4 2024.
- FDA selected nomlabofusp for START pilot to accelerate development; BLA submission targeted 2H 2025.
- Planning PK run-in study in adolescents by year-end 2024; global confirmatory study by mid-2025.

## SEC filing metadata
- accession: 0000950170-24-092265
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/0000950170-24-092265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/lrmr-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092265
- JSON: https://secwatch.observer/filing/0000950170-24-092265.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.